Sakar Healthcare Limited (NSE:SAKAR)
835.70
+39.20 (4.92%)
Jun 1, 2026, 3:30 PM IST
Sakar Healthcare Revenue
In the fiscal year ending March 31, 2026, Sakar Healthcare had annual revenue of 2.54B INR with 42.62% growth. Sakar Healthcare had revenue of 712.68M in the quarter ending March 31, 2026, with 40.39% growth.
Revenue
2.54B
Revenue Growth
+42.62%
P/S Ratio
7.32
Revenue / Employee
7.43M
Employees
342
Market Cap
18.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.54B | 759.17M | 42.62% |
| Mar 31, 2025 | 1.78B | 239.40M | 15.53% |
| Mar 31, 2024 | 1.54B | 199.75M | 14.89% |
| Mar 31, 2023 | 1.34B | 50.74M | 3.93% |
| Mar 31, 2022 | 1.29B | 338.06M | 35.47% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Aarti Pharmalabs | 18.29B |
| Innova Captab | 16.30B |
| Solara Active Pharma Sciences | 13.75B |
| Windlas Biotech | 9.04B |
| Orchid Pharma | 8.47B |
| RPG Life Sciences | 7.08B |
| Ind-Swift Laboratories | 6.88B |
Sakar Healthcare News
- 19 days ago - Sakar Healthcare reports 42% revenue growth in Q4FY26 - Business Upturn
- 5 months ago - Sakar Healthcare gets EMA approval to manufacture Imatinib for Accord’s European market - Business Upturn
- 7 months ago - Sakar Healthcare shares rise over 2.5% after securing nine new oncology product approvals across global markets - Business Upturn
- 7 months ago - Sakar Healthcare receives nine new marketing authorisations for Oncology products in EU and emerging markets - Business Upturn